TY - JOUR
T1 - Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression
T2 - Meta-analysis of absolute prefrontal neuro-metabolic concentrations
AU - Arnone, Danilo
AU - Mumuni, Abdul Nashirudeen
AU - Jauhar, Sameer
AU - Condon, Barrie
AU - Cavanagh, Jonathan
N1 - Funding Information:
This study presents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Center at South London and Maudsley NHS Foundation Trust and King׳s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. DA research is supported by the Academy of Medical Sciences (AMS-SGCL8).
Publisher Copyright:
© 2015 Elsevier B.V. and ECNP.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Proton magnetic resonance spectroscopy (1H MRS) measures glutamatergic metabolites namely glutamate and glutamine located in neurons and astrocytes respectively. In this meta-analysis the contribution of glutamatergic neurotransmission to depressive symptoms was evaluated together with other putative prefrontal metabolites described in the pathogenesis of mood disorders, and in relation to treatment effects. A comprehensive literature search up to 2014 identified 17 reports which measured absolute concentrations of neurometabolites in the prefrontal cortex with 1H MRS meeting criteria for inclusion in this meta-analysis. Excess of heterogeneity was investigated with meta-regressions. The analyses showed an exclusive reduction in absolute values of the composite measure of Glutamine and Glutamate (Glx) in the prefrontal cortex in depression, correlating in meta-regression analyses with treatment severity. Glutamate measurements in isolation did not differ vs. healthy controls or in relation to treatment and/or clinical improvement. Similarly there were no significant changes in other neurometabolites at baseline and following treatment. The analysis supports a role for glutamatergic dysfunction in the pathogeneses of mood dysregulation. The reduction in the absolute Glx values in the absence of changes in glutamate levels, suggests a possible modulatory role of astrocytes in the pathophysiology of depression.
AB - Proton magnetic resonance spectroscopy (1H MRS) measures glutamatergic metabolites namely glutamate and glutamine located in neurons and astrocytes respectively. In this meta-analysis the contribution of glutamatergic neurotransmission to depressive symptoms was evaluated together with other putative prefrontal metabolites described in the pathogenesis of mood disorders, and in relation to treatment effects. A comprehensive literature search up to 2014 identified 17 reports which measured absolute concentrations of neurometabolites in the prefrontal cortex with 1H MRS meeting criteria for inclusion in this meta-analysis. Excess of heterogeneity was investigated with meta-regressions. The analyses showed an exclusive reduction in absolute values of the composite measure of Glutamine and Glutamate (Glx) in the prefrontal cortex in depression, correlating in meta-regression analyses with treatment severity. Glutamate measurements in isolation did not differ vs. healthy controls or in relation to treatment and/or clinical improvement. Similarly there were no significant changes in other neurometabolites at baseline and following treatment. The analysis supports a role for glutamatergic dysfunction in the pathogeneses of mood dysregulation. The reduction in the absolute Glx values in the absence of changes in glutamate levels, suggests a possible modulatory role of astrocytes in the pathophysiology of depression.
KW - Affective disorders
KW - Depression
KW - Glutamate
KW - MRS
KW - Magnetic resonance spectroscopy
KW - Meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=84938751724&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938751724&partnerID=8YFLogxK
U2 - 10.1016/j.euroneuro.2015.04.016
DO - 10.1016/j.euroneuro.2015.04.016
M3 - Article
C2 - 26028038
AN - SCOPUS:84938751724
SN - 0924-977X
VL - 25
SP - 1109
EP - 1117
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
IS - 8
ER -